HUE042382T2 - Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra - Google Patents

Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra

Info

Publication number
HUE042382T2
HUE042382T2 HUE14761317A HUE14761317A HUE042382T2 HU E042382 T2 HUE042382 T2 HU E042382T2 HU E14761317 A HUE14761317 A HU E14761317A HU E14761317 A HUE14761317 A HU E14761317A HU E042382 T2 HUE042382 T2 HU E042382T2
Authority
HU
Hungary
Prior art keywords
neoplasia
treatment
disease virus
preparations containing
newcastle disease
Prior art date
Application number
HUE14761317A
Other languages
English (en)
Hungarian (hu)
Inventor
Xing Cheng
Danielle Carroll
Matthew Mccourt
Mark Galinski
Hong Jin
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HUE042382T2 publication Critical patent/HUE042382T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17Newcastle disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE14761317A 2013-09-03 2014-09-02 Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra HUE042382T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03

Publications (1)

Publication Number Publication Date
HUE042382T2 true HUE042382T2 (hu) 2019-06-28

Family

ID=51492938

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14761317A HUE042382T2 (hu) 2013-09-03 2014-09-02 Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra

Country Status (25)

Country Link
US (2) US10519426B2 (https=)
EP (3) EP3041490B1 (https=)
JP (2) JP6557234B2 (https=)
KR (2) KR102285894B1 (https=)
CN (2) CN111944767A (https=)
AU (2) AU2014317215C1 (https=)
CA (1) CA2922071C (https=)
CY (2) CY1121993T1 (https=)
DK (2) DK3041490T3 (https=)
EA (2) EA202191926A3 (https=)
ES (2) ES2914577T3 (https=)
HK (1) HK1231393A1 (https=)
HR (2) HRP20220653T1 (https=)
HU (1) HUE042382T2 (https=)
LT (2) LT3508209T (https=)
ME (1) ME03345B (https=)
MX (2) MX367768B (https=)
PL (2) PL3508209T3 (https=)
PT (2) PT3508209T (https=)
RS (2) RS63291B1 (https=)
SI (2) SI3041490T1 (https=)
SM (2) SMT201900094T1 (https=)
TR (1) TR201902073T4 (https=)
TW (1) TWI653334B (https=)
WO (1) WO2015032755A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
HUE042382T2 (hu) * 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
CN107847610B (zh) * 2015-04-28 2022-02-01 塞维卡有限责任公司 基于piv5的扩增病毒样颗粒
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
EP3246410A1 (en) 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
CN112739359A (zh) * 2018-07-13 2021-04-30 西奈山伊坎医学院 Apmv及其用于治疗癌症的用途
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状rna組成物及び方法
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
US20220396809A1 (en) * 2021-06-03 2022-12-15 University Of Guelph Engineered newcastle disease virus vector and uses thereof
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体:制造方法和用途
WO2025116613A1 (ko) * 2023-11-29 2025-06-05 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
ATE451835T1 (de) * 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (en) * 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP2968525A4 (en) * 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
HUE042382T2 (hu) * 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Also Published As

Publication number Publication date
AU2019204419A1 (en) 2019-07-11
EA202191926A2 (ru) 2021-10-29
PT3041490T (pt) 2019-02-06
SI3041490T1 (sl) 2019-03-29
DK3041490T3 (en) 2019-03-04
ES2708755T3 (es) 2019-04-11
EP3508209A1 (en) 2019-07-10
CY1126790T1 (el) 2024-12-13
EP3041490A1 (en) 2016-07-13
JP6557234B2 (ja) 2019-08-07
HK1225643B (en) 2017-09-15
TW201606079A (zh) 2016-02-16
KR20210048605A (ko) 2021-05-03
WO2015032755A1 (en) 2015-03-12
TWI653334B (zh) 2019-03-11
AU2019204419B2 (en) 2021-09-02
EP4101457A1 (en) 2022-12-14
HRP20220653T1 (hr) 2022-06-24
KR20160047570A (ko) 2016-05-02
CN106163532A (zh) 2016-11-23
CY1121993T1 (el) 2020-10-14
KR102285894B1 (ko) 2021-08-04
HRP20190250T1 (hr) 2019-05-31
EA202191926A3 (ru) 2022-01-31
EA039404B1 (ru) 2022-01-24
MX2016002771A (es) 2016-09-06
KR102310692B1 (ko) 2021-10-12
AU2014317215B2 (en) 2019-03-28
RS58332B1 (sr) 2019-03-29
US20200181581A1 (en) 2020-06-11
PL3041490T3 (pl) 2019-05-31
CA2922071A1 (en) 2015-03-12
MX2019010364A (es) 2019-10-07
PT3508209T (pt) 2022-05-27
JP2016533749A (ja) 2016-11-04
PL3508209T3 (pl) 2022-06-13
US10519426B2 (en) 2019-12-31
ES2914577T3 (es) 2022-06-14
AU2014317215A1 (en) 2016-04-14
JP6862500B2 (ja) 2021-04-21
CN106163532B (zh) 2019-12-31
EP3041490B1 (en) 2018-11-14
JP2019193662A (ja) 2019-11-07
US11471499B2 (en) 2022-10-18
US20160208222A1 (en) 2016-07-21
EP3508209B1 (en) 2022-03-09
HK1231393A1 (zh) 2017-12-22
SMT202200214T1 (it) 2022-07-21
AU2014317215A8 (en) 2016-04-21
CA2922071C (en) 2022-05-03
SI3508209T1 (sl) 2023-01-31
ME03345B (me) 2019-10-20
CN111944767A (zh) 2020-11-17
LT3041490T (lt) 2019-02-25
SMT201900094T1 (it) 2019-02-28
DK3508209T3 (da) 2022-05-30
AU2014317215C1 (en) 2019-09-12
EA201690425A1 (ru) 2016-08-31
LT3508209T (lt) 2022-06-10
TR201902073T4 (tr) 2019-03-21
RS63291B1 (sr) 2022-06-30
MX367768B (es) 2019-09-05

Similar Documents

Publication Publication Date Title
HUE042382T2 (hu) Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
CL2015002570A1 (es) Anticuerpos humanos de la proteína f del virus respiratorio sincitial y métodos de uso de estos
HUE058731T2 (hu) Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
HUE039997T2 (hu) Szulfamoilpirrolamid származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerekként
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
HUE037347T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE037343T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
IL234508B (en) Inhalation of nitric oxide for treating respiratory diseases
SI3594348T1 (sl) Sestavki kratko aktivirajoče rna c/ebp alfa in postopki uporabe
FI20136131A7 (fi) Suoja, kaareva elementti ja suojan käyttö
HUE052541T2 (hu) Immunogén WT-1 peptidek és eljárások azok alkalmazására
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
HUE059544T2 (hu) Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
HUE052223T2 (hu) IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként
HUE052856T2 (hu) Eljárások és gyógyászati készítmények Hepatitis B vírus fertõzés kezelésére
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
HUE059701T2 (hu) Antitestek és felhasználási módszerek
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe